The global biotechnology company Shire Plc offered its latest insights into certain lysosomal diseases (LSDs) through presentations, satellite symposia and booths at the recent 13th annual WORLD Symposium in San Diego, the company said.
The symposium, which
wrapped up on Friday after a week of “shining light
on science, research and clinical trials for lysosomal diseases,”
is aimed at providing an overview of management and diagnostic
options for patients with lysosomal diseases, as well as pointing out
areas that need more clinical or even basic research.
“We are proud of our ongoing commitment to patients
with rare genetic diseases and look forward to showcasing the depth
and breadth of our scientific research across the LSDs,” Dr.
Hartmann Wellhoefer, vice president and
head of Medical Affairs and Genetic Diseases at
Shire, said. “The data … represent our continued focus on
advancing the diagnosis, treatment and management of life-altering
Shire offered its results of a three-year study on
Hunter syndrome’s effects on cognition, an analysis that looked at
defining characteristics of patients with Gaucher disease type III,
and the effects Gaucher disease can have on pregnancy.
Shire provides latest data on Hunter's syndrome, Gaucher disease